Senores Pharmaceuticals IPO Allotment To Be Finalised Today: Check Details

Senores Pharmaceuticals IPO allotment is likely to be finalised today, December 26, 2024, meaning shares will be allotted to successful bidders. This follows a robust subscription of 93.41 times on the final day of bidding on December 24, 2024.

The ₹582.11 crore IPO received an overwhelming response, with investors bidding for 79.72 crore shares, despite only 85.34 lakh shares being available. The demand was notably driven by Qualified Institutional Buyers (QIBs) and Non-Institutional Investors (NIIs). The retail portion was booked 89.23 times. The issue offered a price band of ₹372-391 per share.

How to Check Senores Pharmaceuticals IPO Allotment Status?

Investors can check Senores Pharma IPO allotment status on the official website of the registrar, Link Intime India Pvt Ltd. Additionally, the share allotment can also be verified on the websites of the stock exchanges, National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).

About Senores Pharmaceutical Limited

Senores Pharmaceuticals Limited was incorporated in December 2017 and is engaged in developing and manufacturing a variety of pharmaceutical products. The company primarily targets regulated markets such as the United States, Canada, and the United Kingdom, while also catering to emerging markets.

The company’s product portfolio includes a range of pharmaceutical formulations, such as:

• Amphetamine Sulfate Tablets
• Hydroxychloroquine Sulfate Tablets
• Ketoconazole Tablets
• Butalbital, Acetaminophen, and Caffeine Capsules
• Mexiletine Hydrochloride Capsules
• Ketorolac Tromethamine Tablets
• Diclofenac Potassium Tablets
• Nicardipine Hydrochloride Capsules, and more.

As of September 30, 2024, Senores Pharmaceuticals has launched 55 products across key therapeutic areas, including antibiotics and anti-fungal treatments. The company has built partnerships with distributors and hospitals in several states throughout India.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.